Cipla Q2FY27: consolidated PAT falls 37% YoY on margin squeeze, back in guidance band

Cipla's primary consolidated numbers show PAT of ₹851.5 Cr (₹877.5 Cr attributable to owners), down 37.1% year-on-year from ₹1,353.4 Cr, on revenue from operations of ₹7,403.9 Cr (-2.4% YoY). Sequentially the print improved — PAT up 8.4% QoQ and revenue up 4.0% QoQ from Q1FY27's ₹785.6 Cr/₹7,119.3 Cr — but per the YoY-first read this is a weak quarter, not a turnaround: neither this quarter nor the year-ago quarter carried any exceptional item, so the decline is unadjusted operating weakness rather than a base-effect artifact. Standalone PAT of ₹787.0 Cr was down a similar 35.0% YoY, confirming the trend isn't a consolidation or associate-income quirk.

The squeeze is margin-led. EBITDA margin (PBT before exceptional items/associates, plus finance cost and depreciation, less other income, over revenue from operations) came in at 18.75%, down roughly 622bps from 24.97% a year ago but up about 200bps sequentially from Q1's 16.75% — and back inside management's reaffirmed FY27 guidance band of 18.5-20%, which Q1 had missed. Net profit margin compressed to 11.3% of total income from 17.2% YoY. The drag traces to cost lines rather than materials: employee benefits expense rose 12.2% YoY to ₹1,474.6 Cr, depreciation 16.1% YoY to ₹344.9 Cr, and finance costs 27.0% YoY to ₹16.7 Cr, while cost of materials consumed was flat YoY. Separately, revenue comparability is muddied by a presentation change — marketing/promotional spend is now netted against revenue rather than expensed, understating the reported YoY revenue decline versus the old basis; the QoQ comparison is unaffected since both FY27 quarters use the new method.

The stock went into the print at ₹1,354.1, down 3.2% over the past month of trading.

For context: PAT has now risen for 2 consecutive quarters.

Our pre-result preview had set revenue of ₹7,050-7,200 Cr, PAT of ₹750-900 Cr and an 18-19% EBITDA margin as the on-plan bar, alongside a bullish medium-term Street read (59.5% buy consensus, ₹1,650 target) tempered by FII outflows and Revlimid-cycle risk. The actual print cleared revenue, landed mid-range on PAT and margin, but diluted EPS of ₹10.85 missed the ~₹12.15 expectation, partly reflecting the ₹26.0 Cr minority-interest drag. No separate management press release was available to extract alongside this filing, so this read rests on the numbers and the Q1FY27 concall record, whose defensive tone and cautiously-optimistic short-term outlook are consistent with a quarter that recovered toward, but didn't exceed, the guided margin band. Among the quarter's other developments, a subsidiary USFDA inspection closed with zero observations (Oct 23) — relevant to the four pending US approvals (three respiratory, one peptide) management flagged last call — while a Keytruda biosimilar tie-up with Qilu Pharma (Sep 3) and an HER2 ADC in-license from SBP Group (Aug 31) are pipeline moves without near-term P&L impact, and the NCLT amalgamation notice for Inzpera Healthsciences carries no results impact.